RGLS (Regulus Therapeutics Inc) Gross Margin

Corporate emblem and logo of Regulus (RGLS)

Regulus Therapeutics (RGLS) is accelerating clinical trials through strategic alliances with global pharma behemoths. The gross profit margin clearly demonstrates the financial dynamics, where the 0.00 indicator expresses the state of the metric. Automation of nucleotide synthesis optimizes internal research, reducing the scientific headcount. Patents for microRNA and positive Phase 1 results for polycystic kidney disease therapy strengthen the fundamental potential.

Regulus Therapeutics Inc - RGLS Gross Margin (period 07/04/2022 - 07/05/2025)

Comprehensive metric breakdowns and analytics for Regulus Therapeutics Inc (RGLS)

Fundamental valuation:RGLS - Regulus Therapeutics Inc.
Manufactured product of Regulus Therapeutics, Inc.

Investors must evaluate the sustainability of the Regulus Therapeutics (RGLS) model, given the high development costs of innovative RNA drugs for the treatment of polycystic kidney disease. For the biotech sector, the gap between revenue and direct production costs is critical, as it determines the efficiency of asset capitalization. By analyzing gross margin profitability, one can determine the portion of profit available to cover operating expenses and further scale the business.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Rate MGX (Metagenomi, Inc)|DTIL: Gross Margin|GBIO: Gross Profit Ratio|Gross Profitability Boundless Bio Inc.|Return on Gross Profit Exicure (XCUR)|Gross Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Gross Profit Rate|Mustang Bio, Inc. - Return on Gross Profit|RNAZ - Return on Gross Profit|BNGO: Return on Gross Profit|APDN (Applied DNA Sciences Inc) - Gross Return on Sales|BLUE (Bluebird Bio) - Return on Gross Profit|ImmunoPrecise Antibodies Ltd - Gross Profit Rate|OMGA (Omega Therapeutics Inc) - Gross Margin|Gross Profitability OMIC|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability